Why UCHON? Next-generation technology PA-PRF: Our Solution!
- Alex Tang
- May 21, 2023
- 5 min read
Updated: May 22, 2023
Newest Generation Technology: PA-PRF (Physical Anticoagulant Platelet Rich Fibrin)
After nearly a decade of technological evolution and development, the broad PRP/PRF technology is increasingly being used by more medical experts in different treatment fields. Academic research and discussions have continuously optimized the clinical application of medical technology, while medical technology continues to iterate.
With the advent of the new generation PA-PRF technology, we no longer need to worry about the rapid coagulation of blood during the preparation process, which severely limits the surgical time. The patented technology of Physical Anticoagulant Platelet Rich Fibrin (PA-PRF) makes the entire process of PRF preparation from blood sample collection to the final surgery effortless. Traditional PRP technology has gradually lost its luster since the moment of finding a more advanced PRP preparation scheme that requires no chemical additives, non-autologous biological anticoagulants, and thrombin.
The Physical Anticoagulant Platelet Rich Fibrin (PA-PRF) system, personally developed and designed by Dr. Zhai Yue, the founder of UCHON, has obtained multiple national invention patents and utility model patents, filling several gaps in China's research on human self-healing therapies. The principle is not difficult to understand: research has shown that the key factor causing blood coagulation, thrombin, is most active at 37 degrees Celsius, and once the temperature drops below 10 degrees Celsius, its activity will be significantly reduced. In the PA-PRF technology, the process of blood extraction and centrifugation is strictly limited to a low-temperature environment, which reduces the activity of thrombin and delays the coagulation of blood. At the same time, the three-minute preset centrifugation setting can stably separate the extract under specific speed conditions. This technology not only retains the platelets in traditional PRP technology but also protects the fibrin that would be destroyed in traditional PRP preparation due to the addition of anticoagulants, as well as enriches the concentration of regenerative factors and white blood cells (concentration can reach more than twice that of normal blood). Meanwhile, the Physical Anticoagulant Platelet Rich Fibrin (PA-PRF) can maintain a liquid state without the addition of anticoagulants for more than 30 minutes, providing doctors with more abundant surgical time. From the perspective of maintaining liquid stability, the extract prepared by our Physical Anticoagulant Platelet Rich Fibrin (PA-PRF) system can guarantee a nearly 100% success rate of extraction and maintain an injectable liquid state for an extended period, allowing clinical doctors to use needles as fine as 34G, which is the thinnest needle, for treatment without preoperative anesthesia, minimizing the damage to human tissue and blood vessels during the surgical process. It is precisely because of these groundbreaking technological discoveries that experts can expand this technology to more unknown treatment fields for research and study.
In summary, the physical anticoagulation platelet-rich fibrin (PRF) technique has the following advantages:
Derived from autologous sources: PRF is prepared from the patient's own blood without the addition of potentially harmful additives (unlike traditional PRP, which requires anticoagulants and thrombin). This theoretically eliminates the risk of allergic reactions, infections, and rejection caused by non-autologous additives triggering the body's immune system, ensuring greater safety.
More effective components: Because no additives are used, the fibrin and growth factors in the blood are well-preserved during the extraction process, ensuring a low red blood cell count (compared to other non-patented extraction techniques).
Convenient operation: After collecting the blood, the PRF can be prepared with a one-button centrifuge within three minutes, ensuring stability of the extracted components.
Sufficient surgical time: The patented pure physical anticoagulation preparation technology ensures that up to 30 minutes of surgical time can be provided.
Low surgical risk: In addition to the improved safety mentioned in point 1, the physical anticoagulation PRF technique combines the advantages of traditional PRP and I-PRF. It can maintain liquidity for a longer period of time (>30 minutes) and supports the use of the finest 34-gauge needles for surgical treatment, minimizing the risk of damage to human tissues and blood vessels caused by medical devices and eliminating the use of anesthesia.
Long-lasting effects: PRF prepared by the UCHON patented physical anticoagulation device contains fibrin and various growth factors without adding any anticoagulants (during blood collection) or clotting agents (during injection), which can accurately target and promote repair. The natural coagulation reaction in the body activates repair signals, and the effect can last for 5 to 10 days, continuously promoting repair with more significant therapeutic effects than traditional PRP.
Broad prospects for development: Various plasma preparation techniques from autologous blood and their application in different medical scenarios have been globally recognized. However, traditional PRP and I-PRF techniques still have certain limitations, with relatively few indications beyond sports injuries, joint maintenance, and medical aesthetics. Physical anticoagulation PRF technology breaks through the limitations of traditional techniques and provides more research and clinical practice space for scientific and medical experts. More indications are waiting to be explored, and every new indication discovered will be a breakthrough in treatment options.
Overall, the physical anticoagulation PRF treatment technique has controllable costs in all aspects, from equipment to surgery. The various advantages based on our patented technology make us look forward to working with scientific and medical experts and institutions worldwide to provide a more cost-effective and better choice for overcoming disease and pain to the global population. We earnestly hope that more people with the same vision will join us in benefiting the public with this technology.
Comparative research of PA-PRF, PRP, PFR and I-PRF
The use of different blood-derived products to stimulate the healing and regeneration of soft tissues started more than 40 years ago. At present, the main medical techniques apply to Cosmetic Surgery, Hair Rejuvenation, Pain Management and Dentistry in China are PRP (Platelet-rich plasma), CGF (Concentrate Growth Factors), PRF (Platelet-rich Fibrin) and PA-PRF (Physical Anticoagulant-Platelet Rich Fibrin). PRP is the most common technique on the market due to it can be used for a range of conditions, yet anticoagulants and activators added during PRP operation make it a certain risk. PA-PRF is extracted from whole blood too but it’s autologous with no additives during the operation, which invented by Dr. Yuezhong Zhai in 2015. The following comparison table is showing the difference between PA-PRF & PRP in many aspects.
PRP vs. PA-PRF
PRP | PA-PRF | |
Anticoagulation method | Chemical addition | Physical method |
Anticoagulants | Trisodium citrate/Heparin | / |
Centrifugalties | Twice | Once or twice |
Activators | Thrombin/Calcium | / |
Platelet Concentration | 4-11 times more | 2-10 times more than whole blood |
White Blood Cell Concentration | Less than whole blood | 1-2 times more than whole blood |
Fibrinogen | √ | √ |
Prothrombin | √ | √ |
Injectable | Not available when activated | Available |
Time for procedure | More than 30minutes | More than 30minutes |
Effect time in the body | Absorbed quickly | 5-10 days |
Release evaluation | Release fast but can’t stay long | Mean release, which still effecting after10 days |
PRP has been questioned internationally 22 years ago, owing to the anticoagulant can weaken the effect of the active ingredients in the body, and the activators can causeallergies, it may even cause irreversible coagulation disorder, it’s all the additional anticoagulants and activators to blame. In 2014, Dr. Choukron invented the I-PRF (injectable platelet-rich fibrin) which is an organic compound extracted from the whole blood processed by centrifugation, the use of additions like anticoagulant or activator is not required in the operation of I-PRF, it lows the risk and now widely adopted in Western developed countries, though it can’t leave much time for doctors to operate. Dr. Yuezhong Zhai upgraded the preparation of PRP to PA-PRF which additions are not necessary and offers more than 30 minutes procedure time due to its temperature being controlled under the coagulation point, Dr. Yuezhong Zhai designed a set of equipment and market launched in 2015, PA-PRF now is gradually accepted by hospitals and doctors in China, It not only solves the problem that PRP needs to use anticoagulants and activators that have certain risk, but also solves the problem that I-PRF can’t allow the doctors enough time to complete the procedure unhurriedly and cannot be injected with very fine needles, which is that PA-PRF can meet various clinical needs.
PA-PRF vs. PFR vs. I-PRF
| PA-PRF | PRF | I-PRF |
Anticoagulation method | physics | Not anticoagulant | physics |
anticoagulant | / | / | / |
Number of separations | Once or twice | Once | Once |
Activator | Not needed | Not needed | Not needed |
Platelet concentration | 2 - 10 times | 2 times | 2 times |
White blood cell concentration | 1 - 2 times | 2 times | 2 times |
fibrinogen | √ | / | √ |
Prothrombin | √ | / | √ |
Fibrin | / | √ | √ |
thrombin | / | √ | √ |
Injection needle | 34g needle | 16g needle | 21g needle |
Time for procedure | More than 30 minutes | 5 minutes | 5 minutes |
Effect time in the body | 5 - 10 days | 5 - 10 days | 5 - 10 days |
Whether it causes embolism | No | Possible | Possible |